
## William J Bowers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10617116/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Application to Gene Therapy and Vaccination. , 2017, , 885-906.		0
2	SEMA4D compromises blood–brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiology of Disease, 2015, 73, 254-268.	2.1	84
3	Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies. Cancer Immunology Research, 2015, 3, 689-701.	1.6	95
4	Drp1 inhibition attenuates neurotoxicity and dopamine release deficits in vivo. Nature Communications, 2014, 5, 5244.	5.8	171
5	Chronic Neuron- and Age-Selective Down-Regulation of TNF Receptor Expression in Triple-Transgenic Alzheimer Disease Mice Leads to Significant Modulation of Amyloid- and Tau-Related Pathologies. American Journal of Pathology, 2013, 182, 2285-2297.	1.9	44
6	Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System. Journal of NeuroImmune Pharmacology, 2012, 7, 42-59.	2.1	284
7	Ablation of TNF-RI/RII Expression in Alzheimer's Disease Mice Leads to an Unexpected Enhancement of Pathology. American Journal of Pathology, 2011, 179, 2053-2070.	1.9	91
8	Robust antigen-specific humoral immune responses to sublingually delivered adenoviral vectors encoding HIV-1 Env: Association with mucoadhesion and efficient penetration of the sublingual barrier. Vaccine, 2011, 29, 7080-7089.	1.7	16
9	CD4+ T Cell Effects on CD8+ T Cell Location Defined Using Bioluminescence. PLoS ONE, 2011, 6, e16222.	1.1	5
10	Biochemical and Morphological Characterization of the AβPP/PS/Tau Triple Transgenic Mouse Model and Its Relevance to Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 361-376.	1.2	18
11	Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional †detour' in the hemisected spinal cord. European Journal of Neuroscience, 2011, 34, 1256-1267.	1.2	58
12	An Alzheimer's diseaseâ€relevant presenilinâ€1 mutation augments amyloidâ€betaâ€induced oligodendrocyte dysfunction. Clia, 2011, 59, 627-640.	2.5	52
13	Genetic therapy for the nervous system. Human Molecular Genetics, 2011, 20, R28-R41.	1.4	62
14	Chondroitinase ABC Combined with Neurotrophin NT-3 Secretion and NR2D Expression Promotes Axonal Plasticity and Functional Recovery in Rats with Lateral Hemisection of the Spinal Cord. Journal of Neuroscience, 2011, 31, 17788-17799.	1.7	102
15	Targeting the Central Nervous System with Herpes Simplex Virus / Sleeping Beauty Hybrid Amplicon Vectors. Current Gene Therapy, 2011, 11, 332-340.	0.9	15
16	Impaired TNF-α control of IP3R-mediated Ca2+ release in Alzheimer's disease mouse neurons. Cellular Signalling, 2010, 22, 519-526.	1.7	12
17	Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cellular Signalling, 2010, 22, 977-983.	1.7	235
18	An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. Journal of Neuroscience Methods, 2010, 190, 171-179.	1.3	76

WILLIAM J BOWERS

#	Article	IF	CITATIONS
19	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	15.2	342
20	Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF. Journal of Neuroscience, 2010, 30, 9567-9577.	1.7	113
21	Virion-Associated Cofactor High-Mobility Group DNA-Binding Protein-1 Facilitates Transposition from the Herpes Simplex Virus/Sleeping BeautyAmplicon Vector Platform. Human Gene Therapy, 2010, 21, 1615-1622.	1.4	12
22	Herpes Simplex Virus/Sleeping Beauty Vector-Based Embryonic Gene Transfer Using the HSB5 Mutant: Loss of Apparent Transposition Hyperactivity In Vivo. Human Gene Therapy, 2010, 21, 1603-1613.	1.4	12
23	Aβ-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice. Molecular Therapy, 2010, 18, 1471-1481.	3.7	66
24	Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target. American Journal of Pathology, 2010, 177, 1422-1435.	1.9	178
25	Tumor Necrosis Factor-α-mediated Regulation of the Inositol 1,4,5-Trisphosphate Receptor Promoter. Journal of Biological Chemistry, 2009, 284, 27557-27566.	1.6	26
26	Effects of Herpes Simplex Virus Amplicon Transduction on Murine Dendritic Cells. Human Gene Therapy, 2009, 20, 442-452.	1.4	4
27	Herpes Virus Amplicon Vectors. Viruses, 2009, 1, 594-629.	1.5	26
28	Dysfunctional memory CD8+ T cells after priming in the absence of the cell cycle regulator E2F4. Cellular Immunology, 2009, 257, 44-54.	1.4	7
29	Tripleâ€ŧransgenic Alzheimer's disease mice exhibit regionâ€specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia, 2009, 57, 54-65.	2.5	199
30	Interferon-γ Differentially Affects Alzheimer's Disease Pathologies and Induces Neurogenesis in Triple Transgenic-AD Mice. American Journal of Pathology, 2009, 175, 2076-2088.	1.9	92
31	Generating Differentially Targeted Amyloid-β Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. Molecular Therapy, 2009, 17, 2031-2040.	3.7	43
32	HSV ICPO recruits USP7 to modulate TLR-mediated innate response. Blood, 2009, 113, 3264-3275.	0.6	126
33	Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. Cancer Immunology, Immunotherapy, 2008, 57, 663-675.	2.0	3
34	Hexamethylene bisacetamide leads to reduced helper virusâ€free HSVâ€1 amplicon expression titers via suppression of ICP0. Journal of Gene Medicine, 2008, 10, 152-164.	1.4	7
35	Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neuroscience, 2008, 9, 81.	0.8	199
36	Chronic Neuron-Specific Tumor Necrosis Factor-Alpha Expression Enhances the Local Inflammatory Environment Ultimately Leading to Neuronal Death in 3xTg-AD Mice. American Journal of Pathology, 2008, 173, 1768-1782.	1.9	205

WILLIAM J BOWERS

#	Article	lF	CITATIONS
37	Tumor Necrosis Factor-α Potentiates Intraneuronal Ca2+ Signaling via Regulation of the Inositol 1,4,5-Trisphosphate Receptor. Journal of Biological Chemistry, 2008, 283, 33069-33079.	1.6	40
38	Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid-β and Interleukin-4. Molecular Therapy, 2008, 16, 845-853.	3.7	49
39	Neuronal Specificity of HSV/Sleeping Beauty Amplicon Transduction In Utero Is Driven Primarily by Tropism and Cell Type Composition. Molecular Therapy, 2007, 15, 1848-1855.	3.7	17
40	Imaging CD8+ T cell dynamics in vivo using a transgenic luciferase reporter. International Immunology, 2007, 19, 1165-1173.	1.8	23
41	Adoptively Transferred Tumor-Specific T Cells Stimulated <i>Ex vivo</i> Using Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor Activity <i>In vivo</i> . Cancer Research, 2007, 67, 10027-10037.	0.4	17
42	Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine, 2007, 25, 1634-1646.	1.7	14
43	HSV-1 amplicon vectors elicit polyfunctional T cell responses to HIV-1 Env, and strongly boost responses to an adenovirus prime. Vaccine, 2007, 25, 7410-7421.	1.7	9
44	Spatial And Temporal Expression of Herpes Simplex Virus Type 1 Amplicon-Encoded Genes: Implications for Their Use As Immunization Vectors. Human Gene Therapy, 2007, 18, 93-105.	1.4	15
45	Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Brain Research, 2007, 1134, 33-44.	1.1	12
46	Infectivity of herpes simplex virus type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging. Journal of Virological Methods, 2007, 145, 37-46.	1.0	2
47	Combined delivery of neurotrophin-3 and NMDA receptors 2D subunit strengthens synaptic transmission in contused and staggered double hemisected spinal cord of neonatal rat. Experimental Neurology, 2006, 197, 347-352.	2.0	33
48	HSV Amplicons: Neuro Applications. Current Gene Therapy, 2006, 6, 337-350.	0.9	9
49	Neuronal Precursor-Restricted Transduction via in Utero CNS Gene Delivery of a Novel Bipartite HSV Amplicon/Transposase Hybrid Vector. Molecular Therapy, 2006, 13, 580-588.	3.7	57
50	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	1.5	44
51	HSV amplicon-mediated AÎ <sup>2</sup> vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiology of Aging, 2005, 26, 393-407.	1.5	44
52	Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. Journal of Neuroinflammation, 2005, 2, 23.	3.1	213
53	Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2005, 12, 1025-1036.	0.7	20
54	Immune Shaping and the Development of Alzheimer's Disease Vaccines. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe35-pe35.	0.9	5

WILLIAM J BOWERS

#	Article	IF	CITATIONS
55	HSV Encoded ICP-0 Inhibits TLR Signaling in CLL Cells by Targeting TRAF-6 Blood, 2005, 106, 2953-2953.	0.6	Ο
56	Viral Delivery of NR2D Subunits Reduces Mg2+ Block of NMDA Receptor and Restores NT-3-Induced Potentiation of AMPA-Kainate Responses in Maturing Rat Motoneurons. Journal of Neurophysiology, 2004, 92, 2394-2404.	0.9	34
57	Cellular immune responses to helper-free HSV-1 amplicon particles encoding HIV-1 gp120 are enhanced by DNA priming. Vaccine, 2003, 21, 2288-2297.	1.7	14
58	Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Molecular Therapy, 2003, 7, 218-227.	3.7	63
59	Neurotrophin-3 Transduction Attenuates Cisplatin Spiral Ganglion Neuron Ototoxicity in the Cochlea. Molecular Therapy, 2002, 6, 12-18.	3.7	101
60	Reporter Gene Transfer Induces Apoptosis in Primary Cortical Neurons. Molecular Therapy, 2002, 5, 723-730.	3.7	66
61	Expression of Human Immunodeficiency Virus Type 1 gp120 from Herpes Simplex Virus Type 1-Derived Amplicons Results in Potent, Specific, and Durable Cellular and Humoral Immune Responses. Journal of Virology, 2002, 76, 5565-5580.	1.5	60
62	Amyloid immunotherapy-engendered CNS inflammation. Neurobiology of Aging, 2002, 23, 675-676.	1.5	9
63	HSV Amplicon-Mediated Delivery of LIGHT Enhances the Antigen-Presenting Capacity of Chronic Lymphocytic Leukemia. Molecular Therapy, 2002, 6, 455-463.	3.7	18
64	HSV Amplicon Vectors in Neuronal Apoptosis Studies. , 2002, , 061-082.		0
65	Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Research, 2002, 62, 6545-51.	0.4	22
66	Dendritic Cells Transduced with HSV-1 Amplicons Expressing Prostate-Specific Antigen Generate Antitumor Immunity in Mice. Human Gene Therapy, 2001, 12, 1867-1879.	1.4	50
67	Development of herpes simplex virus-1 amplicon–based immunotherapy for chronic lymphocytic leukemia. Blood, 2001, 98, 287-295.	0.6	59
68	Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature, 2001, 410, 89-93.	13.7	234
69	HSV Amplicon-Mediated Neurotrophin-3 Expression Protects Murine Spiral Ganglion Neurons from Cisplatin-Induced Damage. Molecular Therapy, 2001, 3, 958-963.	3.7	78
70	Enhanced Learning in Mice Parallels Vector-Mediated Nerve Growth Factor Expression in Hippocampus. Human Gene Therapy, 2000, 11, 2341-2352.	1.4	25